NCT02514681View on ClinicalTrials.gov

A Phase III Trial of Pertuzumab Retreatment in Previously Pertuzumab Treated Her2-Positive Advanced Breast Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

226

Participants

Timeline

Start Date

August 1, 2015

Primary Completion Date

December 31, 2018

Study Completion Date

August 10, 2022

Conditions
HER2-positive Locally Advanced or Metastatic Breast Cancer
Interventions
DRUG

Trastuzumab

DRUG

Pertuzumab

DRUG

Docetaxel

DRUG

Paclitaxel

DRUG

Nab-paclitaxel

DRUG

Vinorelbine

DRUG

Eribulin

DRUG

Capecitabine

DRUG

Gemcitabine

Trial Locations (3)

1030016

Japan Breast Cancer Research Group, Chuo-ku, Nihonbashi, Koami-cho

4648681

Aichi Cancer Center, Chikusa-ku

8608556

Kumamoto University Hospital, Kumamoto

Sponsors

Collaborators (1)

Chugai Pharmaceutical
All Listed Sponsors
collaborator

Chugai Pharmaceutical

INDUSTRY

lead

Japan Breast Cancer Research Group

OTHER